Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Aug
30
Today In Oncology
Large Multicenter Study Evaluates LITT for Primary and Metastatic Brain Tumors
Tissue-Free ctDNA Assay May Help Identify Recurrence Risk in Early Triple-Negative Breast Cancer
Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer
In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles
cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo